<DOC>
	<DOCNO>NCT01050478</DOCNO>
	<brief_summary>This study investigate effect paliperidone ER ( combination without benzodiazepine ) patient present symptom agitation and/or aggression context psychosis , generate data regard efficacy safety acute setting .</brief_summary>
	<brief_title>IMPACT : A Study Explore Efficacy Safety Paliperidone ER Patients With Acute Agitation</brief_title>
	<detailed_description>Psychomotor agitation require hospitalization common event course certain major psychiatric disorder , include schizophrenia . Emergency psychiatric service first doorway control agitation behavioural disturbance mentally ill order avoid dangerousness aggression towards and/or others . The use drug influence psychological behaviour ( psychotropic drug ) help handle agitation aggression , rapidly render people calm and/or sedate without produce distress dangerous adverse event , facilitate extend assessment definitive treatment . Oral atypical antipsychotic , alone combination benzodiazepine , consider first line treatment patient present emergency ward mild moderate psychotic agitation . Paliperidone new atypical antipsychotic therapeutic agent treatment schizophrenia . Paliperidone extend release ( ER ) might consider treatment option patient present agitation and/or aggression ( combination short term use benzodiazepine ) fast onset action limit long term sedate effect . This open-label , single arm , multicenter , interventional descriptive study collect data efficacy safety first day treatment paliperidone ER patient acute agitation context psychosis psychiatric emergency set . The assessment effectiveness/response base Positive And Negative Syndrome Score Exciting Component ( PANSS-EC ) improvement . Safety evaluation include incidence serious non-serious adverse event . The study end 5 day treatment day discharge hospital , whatever come first . 6 mg ( patient acute exacerbation schizophrenia real-world set initial dose paliperidone 9 mg daily may provide optimal clinical efficacy good tolerability ) tablet , oral , day study duration ( 5 day ) .</detailed_description>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>Patient present acute agitation and/or aggression context psychosis , suspect schizophrenia PANSSEC score &gt; =20 Patient outpatient need hospitalization female patient childbearing potential must negative urine pregnancy test baseline adequate anticonceptive protection sign informed consent Received benzodiazepines 4 hour prior enrolment Received antipsychotic medication 72 hour prior enrolment agitation , aggression violent behaviour necessitates use intramuscular intravenous medication Patient 's preference intramuscular intravenous medication Patient judge high risk suicidal behaviour Pregnant breast feeding female Patient receive clozapine longacting injectable antipsychotic last 3 month Serious unstable medical condition , include know clinically relevant lab abnormality History current symptom tardive dyskinesia History neuroleptic malignant syndrome Participation investigational drug trial 30 day prior selection Inability swallow study medication whole aid water ( chew , dissolve , divide crush study medication allow ) Patients narrow blockage gastrointestinal tract Patients current know history ( past 6 month ) substance dependence accord DSMIV criterion know hypersensitivity paliperidone ER risperidone Employees investigator study centre , person direct involvement propose study study direction investigator study centre , family member employee investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>acute agitation</keyword>
	<keyword>aggression</keyword>
	<keyword>psychosis</keyword>
	<keyword>paliperidone extend release</keyword>
</DOC>